| pubmed-article:3617151 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3617151 | lifeskim:mentions | umls-concept:C0035078 | lld:lifeskim |
| pubmed-article:3617151 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:3617151 | lifeskim:mentions | umls-concept:C0040193 | lld:lifeskim |
| pubmed-article:3617151 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3617151 | pubmed:dateCreated | 1987-8-28 | lld:pubmed |
| pubmed-article:3617151 | pubmed:abstractText | The serum kinetics of an intravenous bolus of a combination of ticarcillin (TIC) (3 g) and clavulanic acid (CLAV) (0.2 g) have been determined in a number of patients with different degrees of renal failure as characterized by creatinine clearance. The volume of distribution for both drugs was unaffected by renal failure. Indices of serum and renal drug clearance were related to the degree of renal failure. TIC was cleared more slowly than CLAV. Anephric patients may have a higher serum clearance of CLAV than patients categorized by creatinine clearance as having severe renal failure; this could be due to an increase in metabolic clearance. Haemodialysis effectively clears both drugs. "Rebound" serum concentrations were consistently observed for TIC, but were observed in only one patient for CLAV. Continuous ambulatory peritoneal dialysis results in significant recovery of both drugs. The dosing requirements for the combination of TIC and CLAV in patients with renal failure are considered. | lld:pubmed |
| pubmed-article:3617151 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3617151 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3617151 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3617151 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3617151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3617151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3617151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3617151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3617151 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3617151 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:3617151 | pubmed:issn | 0163-4356 | lld:pubmed |
| pubmed-article:3617151 | pubmed:author | pubmed-author:HendersonII | lld:pubmed |
| pubmed-article:3617151 | pubmed:author | pubmed-author:StewartM JMJ | lld:pubmed |
| pubmed-article:3617151 | pubmed:author | pubmed-author:WatsonI DID | lld:pubmed |
| pubmed-article:3617151 | pubmed:author | pubmed-author:Boulton-Jones... | lld:pubmed |
| pubmed-article:3617151 | pubmed:author | pubmed-author:PaytonC DCD | lld:pubmed |
| pubmed-article:3617151 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3617151 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:3617151 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3617151 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3617151 | pubmed:pagination | 139-47 | lld:pubmed |
| pubmed-article:3617151 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:meshHeading | pubmed-meshheading:3617151-... | lld:pubmed |
| pubmed-article:3617151 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3617151 | pubmed:articleTitle | Pharmacokinetics of clavulanic acid-potentiated ticarcillin in renal failure. | lld:pubmed |
| pubmed-article:3617151 | pubmed:publicationType | Journal Article | lld:pubmed |
